Intact Therapeutics
- Company typePrivate
- Founded2015
- HeadquartersPalo Alto, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Intact Therapeutics firmographics
Firmographics- Name
- Intact Therapeutics
- Legal name
- Intact Therapeutics, Inc.
- Website
- https://intacttherapeutics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Intact Therapeutics industry classification
Industry- Product category
- Gastrointestinal Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where Intact Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Markets served
Intact Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Clinical-stage biopharmaceutical company developing innovative medicines for gastrointestinal disease. Revenue model likely to include pharmaceutical product sales upon regulatory approval, potentially through licensing agreements or direct commercialization.
Intact Therapeutics product offering
Product offeringCore offering
Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies (smart gels / micelles-based formulations) for the treatment of gastrointestinal (GI) disease. The platform is designed to deliver therapeutics directly to GI tissue, addressing unmet clinical needs and aiming to improve efficacy and reduce systemic side effects relative to conventional systemic drug delivery. The company has no commercially approved products at this stage.
Product overview
Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies for gastrointestinal (GI) disease. The company operates as a single-focus therapeutic development organization without modular products or a platform-plus-components architecture — its portfolio consists of innovative medicines in development targeting GI diseases, though specific named products are not publicly disclosed on the available source pages.
Differentiator
Problem solved
Functional benefit
Products and services
- Localized Drug Delivery Platform (GI) Proprietary next-generation localized drug delivery platform (smart gels / micelles-based) designed for targeted treatment of gastrointestinal diseases. The platform is being developed to deliver therapeutics directly to GI tissue with the goal of improving efficacy and reducing systemic side effects relative to conventional systemic drug delivery. Currently pre-clinical / clinical-stage with no approved products.
Companies that use Intact Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Intact Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Intact Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Stanford University (SMC Stanford)coreStanford University, specifically through its SMC (Stanford Medicine Consortium) program, partners with Intact Therapeutics for research collaboration, academic expertise, and potential co-development opportunities in drug delivery technology.
- UCSF Rosenman InstitutecoreThe UCSF Rosenman Institute, focused on health technology and innovation, provides strategic partnership for Intact Therapeutics including access to medical research expertise and potential clinical collaboration opportunities.
- EncubeminorEncube appears as a partner logo on the Intact Therapeutics website, indicating a strategic relationship possibly related to pharmaceutical development, manufacturing, or commercialization support.
Scale indicators1 record
Recent moves6 records
Expansion highlights3 records
Intact Therapeutics competitors and assessment
Company assessmentDirect peers
- Ironwood Pharmaceuticals: Specialty GI biopharmaceutical company (Linzess/linaclotide) focused on GI diseases — directly comparable in therapeutic area and stage evolution, though at a far larger commercial scale.
- RedHill Biopharma: Specialty biopharma with a GI-dominant commercial portfolio (Talicia, Aemcolo) and pipeline — directly comparable as a small/mid-cap GI specialty therapeutics developer.
- Phathom Pharmaceuticals: Late-stage GI specialty biopharma (Voquezna for H. pylori and erosive esophagitis) — comparable in therapeutic focus and as a similarly scaled pre-commercial GI company.
- Entrega Bio: Developer of a proprietary local drug delivery platform for GI and other tissues (acquired by BioNTech) — directly comparable technology approach to Intact's smart-gel localized delivery concept.
- Ardelyx: GI-focused specialty biopharma (IBSRELA/tenapanor, Xphozah) developing novel mechanism therapies for GI and cardiorenal disease — comparable therapeutic focus and mid-cap specialty pharma positioning.
Emerging players
- Synlogic: Clinical-stage synthetic biology company developing engineered probiotics for GI disorders (e.g., phenylketonuria, IBD) — emerging player using novel biology to address GI unmet need, comparable in stage and innovation orientation.
- Seres Therapeutics: Clinical-stage microbiome therapeutics company with lead GI programs (Vowst, SER-109) — emerging player with partial overlap in novel GI therapeutic modalities and similar development-stage profile.
Broad incumbents
- Takeda Pharmaceutical: Major global biopharma with a leading GI franchise including Entyvio for IBD — broad incumbent comparable in target indications but vastly larger and broader in scope.
- Bausch Health (Salix): Through its Salix franchise, Bausch is a dominant established GI specialty pharma player — relevant incumbent comparable in therapeutic area but not in scale or technology specificity.
- AbbVie: Global biopharma with significant GI exposure through Humira/Skyrizi/Rinvoq in IBD and the former Allergan GI portfolio — broad incumbent operating across many GI indications Intact is targeting.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Intact Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intact Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Intact Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intact Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intact Therapeutics
What does Intact Therapeutics do?
Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies (smart gels / micelles-based formulations) for the treatment of gastrointestinal (GI) disease. The platform is designed to deliver therapeutics directly to GI tissue, addressing unmet clinical needs and aiming to improve efficacy and reduce systemic side effects relative to conventional systemic drug delivery. The company has no commercially approved products at this stage.
Is Intact Therapeutics a public or private company?
Intact Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Intact Therapeutics founded?
Intact Therapeutics was founded in 2015. It employs 1 to 10 people.
Where is Intact Therapeutics based?
Intact Therapeutics is headquartered in Palo Alto, United States, in the North America region.
How does Intact Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Intact Therapeutics's main competitors?
Direct peers on record are Ironwood Pharmaceuticals, RedHill Biopharma, Phathom Pharmaceuticals, Entrega Bio and Ardelyx. Emerging players are Synlogic and Seres Therapeutics. Broad incumbents are Takeda Pharmaceutical, Bausch Health (Salix) and AbbVie.
Does Intact Therapeutics have an API?
No public API is recorded for Intact Therapeutics.
What industry is Intact Therapeutics in?
Intact Therapeutics's product category is Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.